CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) indication : giant cell arteritis
The CADTH Canadian Drug Expert Committee (CDEC) recommends that tocilizumab be reimbursed for the treatment of giant cell arteritis (GCA) in adult patients, if the following criteria and conditions are met. At initiation of therapy, or with relapse, patients should be receiving prednisone. Duration...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
March 29, 2018, 2018
|
| Edition: | Final |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that tocilizumab be reimbursed for the treatment of giant cell arteritis (GCA) in adult patients, if the following criteria and conditions are met. At initiation of therapy, or with relapse, patients should be receiving prednisone. Duration of therapy with tocilizumab should be limited to 52 weeks per treatment course. Patients should be under the care of a physician with experience in the diagnosis and management of GCA. A reduction in price |
|---|---|
| Physical Description: | 1 PDF file (7 pages) |